News round-up for 27 April – 1 May by Bruno Quinney, Content Team at DDW. 

This week, the UK has made headlines for both the investment it has attracted and the clinical trial reforms it has rolled out. Elsewhere, the world’s first antimalarial drug for newborns could soon address a critical unmet need. 

The top stories: 

 

UK leads European biotech investment, BIA reports

UK biotech led investment in the European market in the first quarter of 2026, new figures from the BioIndustry Association (BIA) show. 

Read more… 

UK to introduce clinical trial reforms 

New clinical trial regulations are coming into effect this week in the UK, with the changes being the largest package of reforms in over 20 years.   

Read more… 

 

HIV treatment may have changed ‘evolutionary trajectory’ 

Antiretroviral therapy (ART) against HIV may have altered the course of human evolution, research says.  

Read more… 

 

 

WHO prequalifies world’s first antimalarial drug for newborns 

The world’s first and only malaria drug for newborns has been cleared globally, marking a crucial step towards addressing a long-standing gap in malaria care. 

Read more… 

 


FDA approves first gene therapy for genetic hearing loss 

The US Food and Drug Administration (FDA) has granted accelerated approval for Regeneron Pharmaceuticals’ Otarmeni (lunsotogene parvec-cwha), the first gene therapy and second new molecular entity approved under the FDA Commissioner’s National Priority Voucher programme.   

Read more…